Century Therapeutics Inc

NASDAQ IPSC

Data sourced from

and

Download Data

Century Therapeutics Inc Income Tax Provision 5 year CAGR for the year ending December 31, 2023

Century Therapeutics Inc Income Tax Provision 5 year CAGR is NA for the year ending December 31, 2023. Income Tax Provision is the amount of income tax expenses recorded by a company in a given period. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Century Therapeutics Inc Income Tax Provision for the year ending December 31, 2022 was USD 91.00 K, a 111.63% change year over year.
Century Therapeutics Inc Income Tax Provision for the year ending December 31, 2021 was USD 43.00 K, a -96.04% change year over year.
Century Therapeutics Inc Income Tax Provision for the year ending December 31, 2020 was USD 1.08 M, a -10.33% change year over year.
Century Therapeutics Inc Income Tax Provision for the year ending December 31, 2019 was USD 1.21 M.

NASDAQ: IPSC

Century Therapeutics Inc

CEO	Dr. Osvaldo Flores Ph.D.
IPO Date	June 18, 2021
Location	United States
Headquarters	3675 Market Street, Philadelphia, PA, United States, 19104
Employees	152
Sector	Healthcare
Industry	Biotechnology

Description

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Key trends